Efeito de derivados antraquinônicos análogos da mitoxantrona na modulação da resposta imune: modelo de encefalomielite autoimune experimental e de alergia pulmonar
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora
DOI
Abstract
Mitoxantrone is an antineoplasic agent of the anthracenedione family, capable of reduce T
cell numbers, suppress humoral immunity and in vivo activate suppressor T cells. Multiple
Sclerosis (MS) affects about one million people worldwide, is characterized by an
autoimmune chronic inflammatory demyelinating disease of the central nervous system, and,
in most cases, severe and disabling. Moreover, the current therapy for MS has often
unsatisfactory effects, being still ineffective in relation to its healing and full recovery of
patients in advanced stages. Asthma is a chronic inflammatory disease of the airways that
affects approximately 300 million people worldwide. Currently, the treatment of asthma is
intended to control the disease and the drugs used show systemic side effects that are
generally observed with the use of high doses for long time. In this context, this study aimed
to evaluate the effect of a series of anthraquinone derivatives, analogs of mitoxantrone, in the
modulation of in vitro response of murine macrophages activated with lipopolysaccharide and
IFN-g, and check the action in the modulation of the in vivo immune response of experimental
autoimmune encephalomyelitis (EAE) and pulmonary allergy (PA). In the in vitro stage was
evaluated the cytotoxicity of the compounds and the levels of nitric oxide produced. In the in
vivo stage, the O,O’-bis-(3’-iodopropyl)-1,4-dihidroxyanthraquinone (CS56) derivative was
investigated in the evolution of EAE induced in C57Bl/6 mice by applying MOG35-55, and in
the modulation of PA and PA exacerbation by Rhinovirus, induced in BALB/c mice by
inhalation of dust allergens. The results showed that the structural modifications performed on
the anthraquinone derivatives produced less cytotoxic analogs with high ability to inhibit the
NO concentration. The data obtained in vivo indicate that treatment of EAE with CS56
improves the clinical score of disease and this may be correlated with a reduction in the
release of inflammatory cytokines and chemokines involved in the increase of cells in the
central nervous system. The results of PA model demonstrate that treatment with CS56
improves respiratory mice by reducing the parameters of pulmonary allergy, such as bronchial
hyperresponsiveness, mucus hypersecretion and infiltration of eosinophils. Thus, the data
suggest an immunomodulatory role of the derivative in EAE and PA with potential
therapeutic applicability for asthma and multiple sclerosis.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
